Foghorn Therapeutics Presents New Preclinical Data On FHD-909,; Says 'FHD-909 Demonstrated Favorable Tolerability and Dose-dependent Single Agent Activity in BRG1 Mutated Cancers Preclinically'
Foghorn Therapeutics Presents New Preclinical Data On FHD-909,; Says 'FHD-909 Demonstrated Favorable Tolerability and Dose-dependent Single Agent Activity in BRG1 Mutated Cancers Preclinically'
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.